ESMO 2018 Congress

L'ESMO 2018 aura lieu à Munich du 19 au 23 octobre 2018.

 

L'IFCT à l'ESMO 2017

ESMO 2017 banner

L'IFCT était présent à l'ESMO (Madrid) du 8 au 12 septembre 2017.

Communications orales

Results of the phase III IFCT-0302 trial assessing minimal versus CT-scan-based follow-up for completely resected non-small cell lung cancer (NSCLC)
V. Westeel
Saturday 9 sept., 16.00 -18.00, Presidential Symposium I, Madrid Auditorium
View abstract
Download the ESMO press release and the IFCT press release

Second or 3rd line Nivolumab (Nivo) versus Nivo plus Ipilimumab (Ipi) in Malignant Pleural Mesothelioma (MPM) patients: updated results of the IFCT-1501 MAPS2 randomized phase 2 trial.
Sunday 10 sept., 09.15-10.45, Barcelona Auditorium
G. Zalcman
Download the abstract and the IFCT/AP-HP press release in FR end EN

Posters Discussion

IFCT-1502 CLINIVO: Real-life experience with nivolumab in 600 patients with advanced Non-Small Cell Lung Cancer (NSCLC): efficacy and safety of nivolumab and post-nivolumab treatment in the French Expanded Access Program (EAP)
Sunday 10 sept., 16.30-18.00, Barcelona Auditorium
N. Girard
View abstract
View poster

Ultrasensitive detection of EGFR T790M mutation by droplet digital PCR (ddPCR) in TKI naïve non-small cell lung cancer (NSCLC) harboring EGFR mutation: results of the nationwide program Biomarkers France of the French Cooperative Thoracic Intergroup (IFCT).
Saturday 9 sept., 09:00-10.45, Pamplona Auditorium
C. Leduc
View abstract
View poster

Voir le site du congrès en cliquant ici.

--------------------------------------------------------------------------------------------------------

L'IFCT à l'ESMO 2016

ESMO 2016 banner

Notre étude Biomarqueurs France était une nouvelle fois à l’honneur à l’ESMO (Copenhague) du 7 au 11 octobre avec une communication orale sur une étude ancillaire concernant l’épidémiologie moléculaire des mutations dans le CBNPC :

Clinical and biological characteristics of non-small cell lung cancer (NSCLC) harbouring EGFR mutation : Results of the nationwide programme of the French Cooperative Thoracic Intergroup (IFCT) (C. Leduc)   Abstract

Les études PREDICT.amm, RYTHMIC, STIMULI et IFCT-1003 LADIE seront aussi présentées à l'ESMO :

Posters discussion :
- Cost-effectiveness of KRAS, EGFR and ALK testing for therapeutic decision making of advanced stage non-small cell lung cancer (NSCLC) : The French IFCT-PREDICT.amm study (A. Drezet) Abstract
- Pathological central review of 400 thymic epithelial tumors (TET) : The national network RYTHMIC experience (T. Molina)  Abstract
- Quality of resection and outcome in stage III thymic epithelial tumors (TET) : A retrospective analysis of 150 cases from the national network RYTHMIC experience (M. Bluthgen)  Abstract

Posters :
- STIMULI : A randomised open-label phase II trial of consolidation with nivolumab and ipilimumab in limited-stage SCLC after standard of care chemo-radiotherapy conducted by ETOP and IFCT (D. De Ruysscher) Abstract
- IFCT-1003 LADIE trial : Randomized phase II trial evaluating treatment with EGFR-TKI versus EGFR-TKI associated with anti-estrogen in women with non-squamous advanced stage NSCLC (J. Mazières)
Abstract
Poster

Voir le site du congrès : http://www.esmo.org/Conferences/ESMO-2016-Congress

Lu 2773 fois Dernière modification le 28/09/2017